Advertisement
New Zealand markets closed
  • NZX 50

    12,845.64
    +91.06 (+0.71%)
     
  • NZD/USD

    0.6106
    +0.0009 (+0.15%)
     
  • NZD/EUR

    0.5580
    +0.0012 (+0.22%)
     
  • ALL ORDS

    8,496.80
    -1.90 (-0.02%)
     
  • ASX 200

    8,220.30
    -2.70 (-0.03%)
     
  • OIL

    75.68
    -0.17 (-0.22%)
     
  • GOLD

    2,662.70
    +23.40 (+0.89%)
     
  • NASDAQ

    20,241.76
    -27.10 (-0.13%)
     
  • FTSE

    8,237.73
    -6.01 (-0.07%)
     
  • Dow Jones

    42,454.12
    -57.88 (-0.14%)
     
  • DAX

    19,210.90
    -44.03 (-0.23%)
     
  • Hang Seng

    21,251.98
    +614.74 (+2.98%)
     
  • NIKKEI 225

    39,604.04
    +223.15 (+0.57%)
     
  • NZD/JPY

    90.7240
    +0.2310 (+0.26%)
     

MRNA Gets Positive CHMP Opinion for Updated COVID-19 Jab

Moderna, Inc. MRNA announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency's (EMA) has rendered a positive opinion recommending marketing authorization for its updated formulation of the mRNA-based COVID-19 vaccine, Spikevax, targeting the variant JN.1.

The CHMP recommended marketing approval to Spikevax, targeting the variant JN.1, for active immunization to prevent COVID-19 in individuals aged six months and above.

Pending a decision from the European Commission, the updated COVID-19 mRNA vaccine will be available for the 2024-2025 season.

The CHMP’s decision was based on a combination of manufacturing and preclinical data and previous clinical, non-clinical, and real-world evidence that supported the safety and efficacy of MRNA’s COVID-19 mRNA vaccines.

The above mentioned updated vaccine composition was based on guidance from the EMA's Emergency Task Force, issued in April 2024. The agency recommended that vaccine makers make an updated COVID vaccine tailored to the JN.1 family of Omicron subvariants for the 2024-2025 season.

Shares of Moderna have plunged 26.1% so far this year compared with the industry’s decline of 0.9%.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

Recent Developments Related to MRNA's Updated COVID-19 Jab

Spikevax, targeting the variant JN.1., is currently approved in the United States, the United Kingdom, Japan and Taiwan.

Last month, the FDA approved Spikevax, which targets the KP.2 strain of the virus. The regulatory body also approved the updated mRNA-based COVID-19 vaccine of Pfizer PFE and partner BioNTech BNTX.

While the agency approved the updated formulation of Pfizer/BioNTech’s Comirnaty and Moderna’s Spikevax for use in individuals aged 12 years of age and older, it granted emergency use authorization to low-dose formulations of these vaccines for use in individuals aged six months through 11 years.

The updated vaccine composition is based on guidance from the FDA issued in late June 2024.

In June, the FDA's Vaccines and Related Biological Products Advisory Committee recommended that vaccine makers develop an updated COVID vaccine tailored to the KP.2 strain for use in the United States beginning in the fall of 2024.

We note that vaccine makers PFE, BNTX and MRNA are suffering a sharp drop in product sales and market value as COVID-19 cases have significantly dropped compared with the last couple of years. Though the recent rises in COVID-19 infection cases in the United States could somewhat revive demand for vaccines, a substantial gain in revenues and profits that was observed at the peak of the pandemic looks unlikely.

Zacks Rank & Stock to Consider

Moderna currently carries a Zacks Rank #4 (Sell).

A better-ranked stock in the biotech sector is Krystal Biotech, Inc. KRYS, sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

In the past 60 days, estimates for Krystal Biotech’s 2024 earnings per share have increased from $1.98 to $2.38. Earnings per share estimates for 2025 have improved from $4.33 to $7.31. Year to date, shares of KRYS have risen 50%.

KRYS’ earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, the average surprise being 49.95%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Pfizer Inc. (PFE) : Free Stock Analysis Report

Moderna, Inc. (MRNA) : Free Stock Analysis Report

Krystal Biotech, Inc. (KRYS) : Free Stock Analysis Report

BioNTech SE Sponsored ADR (BNTX) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research